CAMK2A(CAMK2a)
Sign in to save this workspaceUniProt Q9UQM7 · PDB · AlphaFold · Substrate: Autocamtide 2 + Ca-CaM · Clone: full lengthhigh-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Abemaciclib | 99.7% | 0.3% | 91.48 | 0.563 |
| 2 | Brigatinib | 99.7% | 0.3% | 82.96 | 0.513 |
| 3 | Alectinib | 97.7% | 2.3% | 95.49 | 0.651 |
| 4 | Sunitinib | 96.3% | 3.7% | 91.73 | 0.524 |
| 5 | Repotrectinib | 95.9% | 4.1% | 84.21 | 0.608 |
| 6 | Ruxolitinib | 93.0% | 7.0% | 98.25 | 0.592 |
| 7 | Rabusertib | 92.0% | 8.0% | 98.74 | 0.687 |
| 8 | Pacritinib | 90.7% | 9.3% | 88.64 | 0.452 |
| 9 | Midostaurin | 90.6% | 9.4% | 78.64 | 0.500 |
| 10 | Bosutinib | 88.4% | 11.6% | 87.22 | 0.555 |
| 11 | Gilteritinib | 81.9% | 18.1% | 88.97 | 0.506 |
| 12 | Nintedanib | 80.4% | 19.6% | 90.23 | 0.608 |
| 13 | Fedratinib | 68.0% | 32.0% | 96.21 | 0.576 |
| 14 | Baricitinib | 62.8% | 37.2% | 97.99 | 0.616 |
| 15 | Palbociclib | 53.7% | 46.3% | 98.75 | 0.673 |
| 16 | Upadacitinib | 44.8% | 55.2% | 97.98 | 0.663 |
| 17 | Ceritinib | 34.3% | 65.7% | 95.44 | 0.618 |
| 18 | Gefitinib | 29.3% | 70.7% | 99.25 | 0.650 |
| 19 | Defactinib | 28.0% | 72.0% | 92.68 | 0.450 |
| 20 | Axitinib | 25.5% | 74.5% | 93.23 | 0.688 |
Paralog block
CAMK2A, CAMK2B, CAMK2D, CAMK2G
EMT expression
- Mesenchymal log2(TPM+1): 0.45
- Epithelial log2(TPM+1): 0.16
- Fold change: 0.29
- Status: No significant change
High-confidence drugs
- Rabusertib — inh 92.0% · KISS 50.81
- Ruxolitinib — inh 93.0% · KISS 46.53
- Alectinib — inh 97.7% · KISS 40.16
Selectivity landscape vs inhibition on CAMK2A
Each point is one of the 92 approved drugs; color = inhibition % on CAMK2A.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…